NEW YORK — Irish diagnostics firm Trinity Biotech said on Tuesday that it has received CE marking for its Captia SARS-CoV-2 IgG ELISA test.
The test uses a recombinant form of SARS-CoV-2 spike protein to detect immunoglobulin G against the virus. Trinity said that the test, which has demonstrated 100 percent specificity, will have applications in detecting past SARS-CoV-2 infection, monitoring individuals who have received SARS-CoV-2 vaccination, and screening individuals prior to vaccination.